EUVIMED · CrossrefZeitschrift
Clinical and Molecular Hepatology
ISSN 2287-2728 · The Korean Association for the Study of the Liver
Neueste Artikel
Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on “Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis”
Correspondence to editorial on “Molecular determinants of outcome to gemcitabine, cisplatin, and nab-paclitaxel in patients with advanced biliary tract cancer”
Letter to the Editor on “Normal-weight MASLD: reclassification, characteristics, and adverse liver outcomes across diverse populations”
Correspondence to letter to the editor on “Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease”
SGLT2 inhibitor and fibrosis progression in MASLD: Correspondence to letter to the editor on “Comparative risk of fibrosis progression with sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitors in metabolic dysfunction-associated steatotic liver disease and type 2 diabetes mellitus with low-to-intermediate fibrosis”
Correspondence to letter to the editor on “Integrative multi-omics profiling identifies infiltrative hepatocellular carcinoma as an immunotherapy-resistant subtype with distinct molecular features”
The ZJU criteria for HCC recurrence in liver transplantation: Biological insights and future perspectives: Correspondence to editorial on “Preoperative risk assessment of hepatocellular carcinoma recurrence in liver transplant recipients by non-invasive detection of pre-existing genetic lesions”
Beyond BMI in MASLD: Rethinking Lean Phenotypes and Metabolic Risk Stratification: Letter to the Editor on “Normal-weight metabolic dysfunction-associated steatotic liver disease: reclassification, characteristics, and adverse liver outcomes across diverse populations”
Correspondence on reply to “Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD”
Clarifying local price mapping, response thresholds, and re-treatment structure in MASLD cost-effectiveness modeling
PI3K pathway activation as a predictive biomarker in biliary tract cancer: the importance of strict covariate adjustment
From tissue phenotyping to systemic outcomes — the expanding clinical relevance of quantitative liver MRI
Clarifying internal inconsistencies in the economic evaluation of hepatitis C self-testing
Comment on systemic inflammation after TIPS in decompensated cirrhosis
Letter to the editor on “Dissecting antibody-mediated natural killer cell effects reveals a cytotoxic CX3CR1⁺KLRC2⁻CD16hi subset linked to hepatitis B virus outcomes”
Numerical reproducibility and threshold interpretation in MASLD risk stratification
Reference standard and lesion classification in evaluating non-contrast MRI for hepatocellular carcinoma surveillance
Anticoagulation in cirrhosis: from stroke prevention to disease modification?: Editorial on “Oral anticoagulants and hepatic decompensation in patients with cirrhosis and atrial fibrillation: observational study”
Gross morphology in advanced hepatocellular carcinoma: outcome association does not establish treatment-predictive value
From label to trajectory in steatotic liver disease: Editorial on “Dynamic transitions in steatotic liver disease subtypes and risk of liver-related events: a nationwide cohort study”
Beyond Tobacco-Use Transitions: Refining Exposure, Abstinence, and Metabolic Interpretation in Steatotic Liver Disease
Reply to Correspondence: Clarifying Local Control in Radiotherapy Versus Local Ablation for HCC
Prognostic, Not Predictive: Reconsidering the “Immunotherapy-Resistant” Label in Infiltrative Hepatocellular Carcinoma
Interpreting the Association Between Breastfeeding and Hepatitis B Mother-to-Child Transmission
Reply to correspondence on “Anticoagulation in cirrhosis: from stroke prevention to disease modification?”
Correspondence on an Editorial regarding “DNMT1 Conducts the Epigenetic Symphony Shaping MASLD Progression”
Reply to "Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in MASLD"
Correspondence to Editorial on the USF1/HKDC1/SMS Axis in Lenvatinib Resistant and Immune Escape in HCC
Reply to “From Pharmacovigilance to Whole-Person Care: The Urgent Case for Integrating Mental Health into Hepatology”
Beyond BMI in MASLD: Rethinking Lean Phenotypes and Metabolic Risk Stratification: Authors’ reply
EUVIMED